Corporate Headquarters
One MedImmune Way
Gaithersburg, MD 20878
Tel.: (301) 398-0000
Fax: (301) 398-9000
Web site: www.medimmune.com

Counsel
Dewey Ballantine LLP
New York, NY

Independent Auditors
PricewaterhouseCoopers LLP
McLean, VA

Annual Shareholders' Meeting
The next annual meeting of the shareholders will be held on May 19, 2005, 10:00 a.m. at MedImmune's research and development facility and corporate headquarters located at One MedImmune Way, Gaithersburg, MD 20878 (301) 398-0000.

SEC Form 10-K and Requests for Information
A copy of the Company's annual report to the Securities and Exchange Commission on Form 10-K is available without charge upon written request to:

Investor Relations
MedImmune, Inc.
One MedImmune Way
Gaithersburg, MD 20878
         or
IR@MedImmune.com

Transfer Agent and Registrar
American Stock Transfer & Trust Company
40 Wall Street, 46th Floor
New York, NY 10005
(718) 921-8200

Common Stock Prices
MedImmune's stock trades on The Nasdaq National Market under the symbol MEDI. At December 31, 2004, there were 248,499,655 shares of common stock outstanding and 2,046 common stockholders of record. The following table shows the range of high and low prices and year-end closing prices for the common stock for the two most recent fiscal years.

Forward-Looking Statements
Unless otherwise indicated, the information in this annual report is as of December 31, 2004. The statements in this annual report that are not descriptions of historical facts may be forward-looking statements. Those statements involve substantial risks and uncertainties. You can identify those statements by the fact that they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "project" or other terms of similar meaning. Those statements reflect management's current beliefs, and are based on numerous assumptions, which MedImmune cannot control and that may not develop as MedImmune expects. Consequently, actual results may differ materially from those described in the forward-looking statements. Among the factors that could cause actual results to differ materially are the risks, uncertainties and other matters discussed in this report, particularly under the section captioned "Risk Factors." MedImmune cautions that RSV disease and influenza disease targeted by two of MedImmune's products, Synagis and FluMist, respectively, occur primarily during the winter months and MedImmune believes its operating results will reflect that seasonality for the foreseeable future. MedImmune is also developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance is received, such products will ultimately achieve commercial success. This annual report will not be updated as a result of new information or future events except as may be required by applicable law or regulation.